Asia Green Biotechnology Corp. provided an update on the current activities of the Company, which include various developments in SE Asia, where its international efforts are centred, and in Canada, where the Company continues to partner with Pathway Rx Inc. (Pathway) to pursue clinical trials activities in the development of a migraine treatment utilizing cannabis and hemp extracts controlled by Pathway. SE Asia: The Company is developing varieties of hemp with superior growth and production characteristics in the various environments found in its licensed territories. With the data and associated knowledge gained from these activities, the Company intends to leverage the technology to develop a portfolio of strategic hemp investments to take advantage of both the changing social climate relative to hemp use and the historic acceptance of the use of these products and their derivatives in certain of the jurisdictions granted under the License Agreements with InPlanta Biotechnologies Inc. ("InPlanta"), Swysh Inc. ("Swysh") and Pathway. In that vein, the Company continues to work with local partners to create direct programs aimed at facilitating testing and further research in relation to the isolation of new varieties that will thrive in the light and general climactic conditions prevalent in sub-tropical environments often encountered in the licensed regions. Over the course of this program, AGB has at various times established formal and informal relationships with government bodies, academic and research-oriented institutions, and private entities in efforts to
exchange information and skills, access a broader base of intellectual property, and institute detailed testing procedures to achieve those goals. Current activities in SE Asia and Thailand in particular, where liberalization of cannabis/hemp laws are occurring on an accelerated basis, suggest to AGB management that the future of industrial hemp production is very positive in the region, with demand for a flexible, out-of-doors variety remaining very high. This has become the central focus of the research activities in Thailand, with management expanding its capacity to address the potential for new variety development by exploring breeding programs with other entities in SE Asia and elsewhere. With a view to the successful isolation of such varieties, and with the direct participation of InPlanta, the Company has recently delivered a new shipment of InPlanta's Bountiful variety to Thailand, where potential adaptation of Bountiful to local conditions will be explored by through cross-fertilization with local and other sub-tropical strains of industrial hemp. Migraine Study: Through its partner Pathway, the Company continues to work with Health Canada and other service providers to assemble the final elements otherwise required to this undertake this study. The study is a significant part of a wider program to have the exclusive hemp and related cannabinoidal varieties that the Company has access to by virtue of its exclusive licensing agreements with Pathway and Swysh, and possibly other versions of the strains, studied for their efficacy in humans and eventually approved and applied as new drugs and over-the-counter health products. The particular focus of this study and further studies which may be derived from it is on the ability of an element ofa proprietary hemp strain to treat and minimize symptoms in those suffering from migraine headaches. In addition to the suffering of individuals, migraine also has an impact on society which can be measured in both direct costs (medical care etc.) and indirect costs (missed work and disability at work).